[go: up one dir, main page]

RU2018105485A3 - - Google Patents

Download PDF

Info

Publication number
RU2018105485A3
RU2018105485A3 RU2018105485A RU2018105485A RU2018105485A3 RU 2018105485 A3 RU2018105485 A3 RU 2018105485A3 RU 2018105485 A RU2018105485 A RU 2018105485A RU 2018105485 A RU2018105485 A RU 2018105485A RU 2018105485 A3 RU2018105485 A3 RU 2018105485A3
Authority
RU
Russia
Application number
RU2018105485A
Other versions
RU2018105485A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018105485A publication Critical patent/RU2018105485A/ru
Publication of RU2018105485A3 publication Critical patent/RU2018105485A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018105485A 2012-11-29 2018-02-14 Ингибирующие олигонуклеотиды и их применение RU2018105485A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2012/085547 2012-11-29
PCT/CN2012/085547 WO2014082254A1 (en) 2012-11-29 2012-11-29 Inhibitory oligonucleotide and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015120365A Division RU2015120365A (ru) 2012-11-29 2012-11-29 Ингибирующие олигонуклеотиды и их применение

Publications (2)

Publication Number Publication Date
RU2018105485A RU2018105485A (ru) 2019-08-14
RU2018105485A3 true RU2018105485A3 (ru) 2019-08-14

Family

ID=50827048

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015120365A RU2015120365A (ru) 2012-11-29 2012-11-29 Ингибирующие олигонуклеотиды и их применение
RU2018105485A RU2018105485A (ru) 2012-11-29 2018-02-14 Ингибирующие олигонуклеотиды и их применение

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2015120365A RU2015120365A (ru) 2012-11-29 2012-11-29 Ингибирующие олигонуклеотиды и их применение

Country Status (10)

Country Link
US (2) US9688992B2 (ru)
JP (1) JP6106280B2 (ru)
KR (1) KR102027023B1 (ru)
AU (1) AU2012395641B2 (ru)
CA (1) CA2891906A1 (ru)
MX (1) MX369618B (ru)
PH (1) PH12015501182B1 (ru)
RU (2) RU2015120365A (ru)
SG (1) SG11201504142WA (ru)
WO (1) WO2014082254A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688992B2 (en) 2012-11-29 2017-06-27 Sbi Biotech Co., Ltd. Inhibitory oligonucleotide and use thereof
AU2016375543A1 (en) 2015-12-25 2018-06-28 Sbi Biotech Co., Ltd. TLR inhibitory oligonucleotides and their use
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
AU2017277647B2 (en) 2016-06-08 2023-07-27 President And Fellows Of Harvard College Engineered viral vector reduces induction of inflammatory and immune responses
BR112019009469A2 (pt) 2016-11-09 2019-07-30 Pulmotect Inc métodos e composições para a modulação imunológica adaptativa
WO2019094548A1 (en) * 2017-11-08 2019-05-16 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
CN112798796B (zh) * 2021-01-04 2024-02-02 东南大学 一种基于dna-paint的细胞膜上pd-l1蛋白检测方法及序列
WO2022170396A1 (en) * 2021-02-12 2022-08-18 ViraLok Therapeutics Pty Ltd Agents and methods for therapy and prophylaxis
CN116370494A (zh) * 2022-11-14 2023-07-04 南昌大学 CpG寡核苷酸对糖尿病神经病理痛疾病药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072290A2 (en) 2004-01-23 2005-08-11 Joslin Diabetes Center Methods of treating, reducing, or preventing autoimmune conditions
CN102851295B (zh) 2006-08-28 2015-01-07 长春华普生物技术有限公司 Toll 样受体调节性寡核苷酸及其用途
US8030289B2 (en) * 2008-08-06 2011-10-04 Changchun Huapu Biotechnology Co., Ltd. Oligonucleotide and use thereof
CN101643496B (zh) 2008-08-07 2015-09-09 长春华普生物技术有限公司 一种具有免疫抑制功能的寡核苷酸
EP2437791B1 (en) 2009-06-01 2017-03-22 Idera Pharmaceuticals, Inc. Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
US9688992B2 (en) 2012-11-29 2017-06-27 Sbi Biotech Co., Ltd. Inhibitory oligonucleotide and use thereof

Also Published As

Publication number Publication date
MX369618B (es) 2019-11-14
US9688992B2 (en) 2017-06-27
KR102027023B1 (ko) 2019-09-30
WO2014082254A1 (en) 2014-06-05
JP6106280B2 (ja) 2017-03-29
JP2015536659A (ja) 2015-12-24
AU2012395641B2 (en) 2019-10-03
US20150299710A1 (en) 2015-10-22
PH12015501182A1 (en) 2015-08-17
RU2018105485A (ru) 2019-08-14
KR20150089019A (ko) 2015-08-04
MX2015006703A (es) 2015-08-05
RU2015120365A (ru) 2017-01-10
US10190122B2 (en) 2019-01-29
CA2891906A1 (en) 2014-06-05
US20170335325A1 (en) 2017-11-23
SG11201504142WA (en) 2015-06-29
AU2012395641A1 (en) 2015-05-28
PH12015501182B1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
BR112014017635A2 (ru)
BR112014017614A2 (ru)
BR112014017625A2 (ru)
BR112014017659A2 (ru)
BR112014017592A2 (ru)
BR112014017646A2 (ru)
BR112014017607A2 (ru)
BR112014017638A2 (ru)
BR112013027865A2 (ru)
BR112014017609A2 (ru)
BR112014017634A2 (ru)
BR112014017644A2 (ru)
BR112014017588A2 (ru)
BR112014017618A2 (ru)
BR112014017647A2 (ru)
BR112014013184A8 (ru)
BR112014017623A2 (ru)
BR112014017652A2 (ru)
BR112014017630A2 (ru)
BR112014017627A2 (ru)
BR112014017631A2 (ru)
BR112014017641A2 (ru)
BR112014017622A2 (ru)
RU2018105485A3 (ru)
BR112014017589A2 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200310